– USA, NV – Secura Bio, Inc., an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, today announced the additions of Dr. Joerg Moeller (MD) and Chip Romp to its Board of Directors.
“Both Joerg and Chip are welcome additions to the board of directors. As the company continues to grow organically and through future acquisitions of pharmaceutical assets, we anticipate significant benefit from the input and extensive experience of these two senior executives” stated Joseph M. Limber, President and CEO of Secura Bio.
About Dr. Joerg Moeller
Dr. Joerg Moeller has over 30 years of experience in the pharmaceutical industry and a proven track record of developing and launching innovative and competitive drugs in various therapeutic areas including oncology and hematology. He was the former Head of Global Research and Development at Bayer Pharmaceuticals and a member of Bayer Pharma´s Executive Committee. Dr. Moeller was most recently the Global Head of Research and Development at LEO Pharma A/S, a leading dermatology company.
“Secura Bio is dedicated to advancing the standard of care in oncology and I am looking forward to working with the executive team under the leadership of Joseph Limber”, said Dr. Joerg Moeller.
About Charles (Chip) Romp
Chip Romp has over 25 years in the pharmaceutical industry with an emphasis on leading commercial organizations in the oncology and hematology space. He spent 12 years at Genentech in a series of sales and marketing roles spanning their oncology/immunology product portfolio. Mr. Romp is currently EVp of Commercial U.S. at Seagen, Inc. where he is a member of the Executive Committee and oversees its entire Commercial organization.
Chip Romp said, “I am thrilled to join the board of directors and look forward to working with the company’s leadership to improve the lives of patients”.
About Secura Bio, Inc.
Secura Bio is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies for physicians and their patients.
For more information: https://www.securabio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
